Cargando…
A systematic review on the effect of bevacizumab in exudative age-related macular degeneration: a response to a letter to the editor by Schmucker et al.
Autores principales: | Schouten, Jan S. A. G., La Heij, Ellen C., Webers, Carroll A. B., Lundqvist, Igor J., Hendrikse, Fred |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2821519/ http://dx.doi.org/10.1007/s00417-009-1244-x |
Ejemplares similares
-
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
por: Hamid, Mohamed A., et al.
Publicado: (2021) -
Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study
por: Schauwvlieghe, A. M. E., et al.
Publicado: (2016) -
Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration
por: Shaikh, Saad, et al.
Publicado: (2007) -
Retinal pigment epithelial tear after intravitreal bevacizumab injection for exudative age-related macular degeneration
por: Singh, Sunil Kumar, et al.
Publicado: (2014) -
Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
por: Griffin, David R., et al.
Publicado: (2014)